上皮损伤与炎症表型指导ARDS个体化通气:LIVE试验二次分析
该研究为LIVE试验的二次分析,纳入259例有血浆sRAGE检测的局灶性或非局灶性ARDS患者,比较肺复张策略与低PEEP策略。基线sRAGE以2,440 pg/mL二分。高sRAGE组肺复张与90天死亡率降低相关(HR 0.41,95%CI 0.18-0.93),低sRAGE组肺复张与死亡率升高相关(HR 3.27,95%CI 1.06-10.1);炎症表型与死亡率相关(高炎症表型57% vs 26%),但未识别疗效异质性。提示sRAGE可能指导ARDS肺复张的个体化选择。
要点
- 该分析为二次分析,样本量259例,需前瞻性验证sRAGE指导的肺复张策略。
适用人群与场景
- 纳入LIVE试验中有血浆sRAGE测量的259例ARDS患者,包括局灶性或非局灶性ARDS;具体纳入/排除标准未在摘要中详细列出。
诊断标准与关键阈值
- 基线sRAGE水平以2,440 pg/mL为界分为高sRAGE组和低sRAGE组;炎症表型使用验证过的简化模型(IL-8、可溶性肿瘤坏死因子受体1和碳酸氢盐)识别。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:LIVE试验的二次分析;样本量259例;人群:局灶性或非局灶性ARDS患者。
- 干预与对照:肺复张策略 vs 低PEEP策略。
- 敏感性分析未使用逆概率加权,方向一致。
证据类型、等级与局限
- 证据类型:RCT(LIVE试验)的二次分析;证据等级或推荐强度未在摘要中给出;局限包括二次分析、样本量有限(259例),需前瞻性验证。
对床旁实践的改变
- 在ARDS患者中,基线血浆sRAGE水平可能有助于筛选肺复张策略的获益人群:高sRAGE(>2,440 pg/mL)者肺复张与90天死亡率降低相关,低sRAGE者肺复张与死亡率升高相关;该结果来自二次分析,不能作为常规推荐,需前瞻性验证。
- 炎症表型(高炎症 vs 低炎症)可用于预后判断(高炎症表型90天死亡率57% vs 26%),但不宜用于选择肺复张策略。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Guidelines recommend against systematic lung recruitment strategies in ARDS. Soluble receptor for advanced glycation end products (sRAGE), an alveolar epithelial injury plasmatic biomarker, and inflammatory phenotypes may guide personalized approaches.
RESEARCH QUESTION: Does baseline sRAGE or inflammatory phenotype identify heterogeneity in the treatment effect of lung recruitment on mortality in ARDS?
STUDY DESIGN AND METHODS: This analysis included 259 patients with plasma sRAGE measurements from the original Lung Imaging for Ventilator Setting (LIVE) trial that compared lung recruitment with low positive end-expiratory pressure strategies in patients with focal or non-focal ARDS. Baseline sRAGE levels were dichotomized at 2,440 pg/mL into high and low groups. Inflammatory phenotypes were identified using a validated parsimonious model (IL-8, soluble tumor necrosis factor receptor 1, and bicarbonate). The primary and secondary outcomes were 90-day mortality and sRAGE trajectory until day 6. Inverse probability weighting and weighted Cox models were used; sRAGE trajectories were assessed using joint models.
RESULTS: High plasma sRAGE (r = 0.26; P < .001), but not the inflammatory phenotype, was moderately correlated with non-focal ARDS. The treatment effect varied by baseline sRAGE (interaction P = .006), but not by inflammatory phenotype (interaction P = .56); however, the hyperinflammatory phenotype was associated with 90-day mortality (57% vs 26%; P < .001). Among patients with high sRAGE levels, lung recruitment was associated with lower 90-day mortality (hazard ratio, 0.41; 95% CI, 0.18-0.93; P = .033); among patients with low sRAGE levels, it was associated with higher mortality (hazard ratio, 3.27; 95% CI, 1.06-10.1; P = .039). Lung recruitment was associated with different sRAGE slopes compared with low positive end-expiratory pressure, with effect modification by baseline sRAGE. Lung recruitment was associated with a steeper decline in sRAGE among patients with high baseline sRAGE levels (interaction P < .001), and with a slower decline among patients with low baseline sRAGE levels (interaction P = .038). Inflammatory phenotypes did not identify heterogeneity of treatment effect. Sensitivity analyses without inverse probability weighting were directionally consistent.
INTERPRETATION: Our results show that, in ARDS, epithelial injury assessed by plasma sRAGE may identify heterogeneity of treatment effect with lung recruitment, whereas inflammatory phenotypes remain prognostic for mortality.
参考来源
- Pensier J, Renard-Triché L, Theilliere C, et al. Epithelial Injury and Inflammatory Phenotypes for Personalized Ventilation in ARDS: Secondary Analysis of the Lung Imaging for Ventilator Setting Trial. Chest. 2026. PMID: 42777910. doi:10.1016/j.chest.2026.08.054
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。